El-Hibri Fuad Form 4 March 16, 2012

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person \* El-Hibri Fuad

2. Issuer Name and Ticker or Trading Symbol

Emergent BioSolutions Inc. [EBS]

5. Relationship of Reporting Person(s) to

Issuer

(Last)

400

(First)

2273 RESEARCH BLVD., SUITE

(Street)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

\_X\_\_ 10% Owner \_X\_\_ Director

(Check all applicable)

03/13/2012

X\_ Officer (give title \_ Other (specify below) CEO & Chairman

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting Person

#### ROCKVILLE, MD 20850

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secur	ities Acq	uired, Disposed o	of, or Benefici	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	wnership Indirect orm: Beneficial irect (D) Ownership	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	
Common Stock	03/13/2012		A	16,050 (1)	A	\$0	1,517,918	D	
Common Stock	03/14/2012		F	3,538	D	\$ 16.05	1,514,380 (2)	D	
Common Stock							15,769 <u>(3)</u>	I	By Karim El-Hibri Trust
Common Stock							15,769 <u>(3)</u>	I	By Yusra El-Hibri Trust
							15,769 (3)	I	

#### Edgar Filing: El-Hibri Fuad - Form 4

Common Stock		By Faiza El-Hibri Trust					
Common Stock	5,636,794 (4) I	By Intervac, L.L.C.					
Common Stock	1,524,155 (5) I	By Biovac, L.L.C.					
Common Stock	1,565,043 <u>(6)</u> I	By BioPharm, L.L.C.					
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.							

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	\$ 15.83	03/13/2012		A	32,100	<u>(7)</u>	03/14/2019	Common Stock	32,100

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
· ·	Director	10% Owner	Officer	Other		
El-Hibri Fuad						
2273 RESEARCH BLVD., SUITE 400	X	X	CEO & Chairman			
ROCKVILLE, MD 20850						

2 Reporting Owners

Edgar Filing: El-Hibri Fuad - Form 4

## **Signatures**

/s/ Carl A. Valenstein, attorney-in-fact

03/16/2012

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming (1) continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- (2) Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, an aggregate 41.1072% equity interest in Intervac, L.L.C. Intervac, L.L.C. is (4) the direct owner of 5,636,794 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 2,317,129 shares.
- Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, (5) L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
- Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 1,565,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 628,678 shares.
- (7) Exercisable in three equal installments on March 12, 2013, March 12, 2014 and March 12, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3